Arizona is currently home to 1653 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study
NCT05053100
Recruiting
This study evaluates the risks and experience of blood clots and bleeding in patients with blood cancers. While it is standard of care to use medications to reduce the risk of blood clots in hospitalized individuals, some patients with blood cancers have low platelet counts that can increase the concern for bleeding complications associated with these medications. At this time, the optimal management strategies for blood clots are not well known for patients with blood cancers. This pilot study... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Acute Leukemia, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Thrombocytopenia
Register for Updates
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646
Recruiting
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an... Read More
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
10/24/2023
Locations: ACTION3 Investigational Site 4, Phoenix, Arizona
Conditions: FSGS
Register for Updates
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971
Recruiting
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/17/2023
Locations: Arizona Research Clinic, PLLC, Chandler, Arizona
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Register for Updates
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
NCT03129139
Recruiting
A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Mayo Clinic Arizona, Phoenix, Arizona
Conditions: Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
Register for Updates
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
NCT04042831
Recruiting
This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2023
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion
Register for Updates
FX Shoulder Solutions Retrospective / Prospective Clinical Study
NCT06077942
Recruiting
Subjects implanted with the shoulder replacement medical devices manufactured by FX Shoulder Solutions and distributed by FX Shoulder Solutions.
Gender:
ALL
Ages:
All
Trial Updated:
10/10/2023
Locations: OrthoArizona, Gilbert, Arizona
Conditions: Rotator Cuff Syndrome of Shoulder and Allied Disorders, Osteoarthritis Shoulder, Fracture, Shoulder
Register for Updates
Desara ® One Single Incision Sling 522 Study
NCT04772131
Recruiting
A post-market study to compare the safety and effectiveness of the Desara® One Single Incision Sling (SIS), when compared to that of an FDA cleared transobturator sling over a period of 36 months.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/09/2023
Locations: Valley Urogynecology Associates, Inc., Phoenix, Arizona
Conditions: Stress Urinary Incontinence
Register for Updates
Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)
NCT03420014
Recruiting
The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in metastatic leiomyosarcoma patients.
Gender:
ALL
Ages:
Between 16 years and 100 years
Trial Updated:
10/06/2023
Locations: Mayo Clinic Hospital, Phoenix, Arizona
Conditions: Leiomyosarcoma
Register for Updates
FX Shoulder Prospective Clinical Study
NCT06078865
Recruiting
Prospective Multi-Center Registry on study subjects with implanted devices marketed and legally commercialized in the USA by FX Shoulder Solutions.
Gender:
ALL
Ages:
All
Trial Updated:
10/05/2023
Locations: OrthoArizona, Gilbert, Arizona
Conditions: Osteoarthritis Shoulder, Rotator Cuff Syndrome of Shoulder and Allied Disorders, Fracture, Shoulder
Register for Updates
A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function
NCT04398680
Recruiting
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and in matched RRMM participants with normal hepatic function.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2023
Locations: GSK Investigational Site, Tucson, Arizona
Conditions: Multiple Myeloma
Register for Updates
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
NCT04892472
Recruiting
This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System with IV pembrolizumab in subjects previously untreated for advanced or metastatic, PD-L1 positive non-small cell lung cancer (NSCLC). The primary objective is to evaluate the progression-free survival (PFS) by RECIST 1.1 in subjects with TPS ≥1 percent, 1L metastatic/current advanced NSCLC treated with TTFields concomitant with pembrolizumab compared to t... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
10/04/2023
Locations: Palo Verde Cancer Specialists, Glendale, Arizona
Conditions: Non-small Cell Lung Cancer
Register for Updates
Post-Approval Study of the TREO Abdominal Stent-Graft System
NCT04697784
Recruiting
The purpose of this study is to determine the long-term performance of the TREO Abdominal Stent-Graft as a treatment for patients with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2023
Locations: Banner University Medical Center, Phoenix, Arizona
Conditions: Abdominal Aortic Aneurysm
Register for Updates